FY2023 EPS Estimates for BioSig Technologies, Inc. (NASDAQ:BSGM) Decreased by Analyst

BioSig Technologies, Inc. (NASDAQ:BSGM) – Analysts at Taglich Brothers dropped their FY2023 EPS estimates for shares of BioSig Technologies in a research report issued on Tuesday, September 12th. Taglich Brothers analyst H. Halpern now forecasts that the company will earn ($0.42) per share for the year, down from their prior estimate of ($0.35). The consensus estimate for BioSig Technologies’ current full-year earnings is ($0.35) per share. Taglich Brothers also issued estimates for BioSig Technologies’ Q1 2024 earnings at ($0.06) EPS, Q2 2024 earnings at ($0.06) EPS and FY2024 earnings at ($0.24) EPS.

BioSig Technologies Stock Up 15.5 %

BioSig Technologies stock opened at $0.50 on Friday. BioSig Technologies has a 1-year low of $0.25 and a 1-year high of $1.65. The firm’s 50 day simple moving average is $0.76 and its 200 day simple moving average is $1.06.

Hedge Funds Weigh In On BioSig Technologies

A number of hedge funds and other institutional investors have recently bought and sold shares of BSGM. Advisor Resource Council purchased a new position in BioSig Technologies in the 1st quarter worth approximately $1,035,000. Geode Capital Management LLC grew its stake in BioSig Technologies by 67.0% in the 2nd quarter. Geode Capital Management LLC now owns 565,738 shares of the company’s stock worth $707,000 after buying an additional 227,054 shares in the last quarter. BlackRock Inc. boosted its stake in shares of BioSig Technologies by 32.1% in the 2nd quarter. BlackRock Inc. now owns 594,162 shares of the company’s stock valued at $743,000 after purchasing an additional 144,300 shares in the last quarter. Cambridge Investment Research Advisors Inc. boosted its stake in shares of BioSig Technologies by 34.7% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 324,189 shares of the company’s stock valued at $373,000 after purchasing an additional 83,600 shares in the last quarter. Finally, Sequoia Financial Advisors LLC purchased a new stake in shares of BioSig Technologies in the 2nd quarter valued at $88,000. Hedge funds and other institutional investors own 7.16% of the company’s stock.

About BioSig Technologies

BioSig Technologies, Inc, together with its subsidiaries, a medical device company, commercializes advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias. The company offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures.